METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on stomach cancer shows promise in small trial
Disease control CompletedThis phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug cocktail shows promise for tough stomach cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control CompletedThis study tested two drugs, olaparib and ramucirumab, in 51 people with advanced stomach or gastroesophageal junction cancer that had spread or could not be removed. The goal was to find the best dose and see how well the combination worked. The trial is complete, and results ma…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC